Home » Newsletters » BioWorld Science

BioWorld Science

July 25, 2012

View Archived Issues

Researchers at Leo Pharma patent novel ingenol compounds

Candidate Syntaxin drug for acromegaly has new mode of action

New NK3 receptor antagonists presented by Roche

New antifungals prepared at Janssen Pharmaceutica

Eutropics Pharmaceuticals discloses novel Mcl-1/Bcl-XL inhibitors

New IGF-I receptor inhibitors reported by Boehringer Ingelheim

Janssen Pharmaceutica divulges new BACE1 inhibitors

Belgian-Dutch collaboration yields candidate biomarker for use in kidney transplant recipients

Novel OGA inhibitors designed

BioCryst reports on two phase II trials of BCX-4208

Data presented on sustained-release plug for glaucoma

Recruitment begins in phase II NKTR-181 trial

First preclinical candidate drug selected in osteoarthritis alliance

Merck & Co. provides update on anti-HIV drug development

Dynavax submits MAA for Heplisav hepatitis B vaccine

Sarepta drug shows clinical benefit in Duchenne muscular dystrophy

Ongoing conference features new data on anti-HIV/HSV combination gel

Pfizer reports topline results from first of four phase III bapineuzumab studies

First patient treated in study of subcutaneous Debio-8206

Biofrontera holds meeting with FDA regarding planned application for Ameluz

FDA grants priority review to enzalutamide NDA

FDA issues safety communication regarding Ampyra

Anticancer drug shows promise to treat Alzheimer's disease

Psyadon halts ecopipam study based on promising interim results

SRI receives NIAID grant for development of bioadhesive gel

European Commission approves combination tablet for type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...